European Heart Journal Advance Access originally published online on November 26, 2008
European Heart Journal 2009 30(2):152-161; doi:10.1093/eurheartj/ehn510
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2008 The European Society of Cardiology and Europa Edition. All rights reserved. For permissions please email: journals.permissions@oxfordjournals.org
Meeting Report
ESC Forum on Drug Eluting Stents European Heart House, Nice, 27–28 September 2007
Authors/writing members:,
Participants in the Forum:,
1 Thoraxcenter, Erasmus MC, Rotterdam, the Netherlands
2 Cardiovascular Center, OLV Hospital, Aalst, Belgium
3 University of Liverpool, UK
4 KEMA Medical, Arnhem, München, Tel Aviv, Chalfont PA, Lafayette CA, Tokyo
5 Programs for Assessment of Technology in Health (PATH) Research Institute, St Joseph's Healthcare Hamilton/Mc Master University, Hamilton, ON, Canada
6 TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
7 University of Geneva, Geneva, Switzerland
8 Institut Cardiovasculaire Paris Sud, Massy, France
9 NHLI, Imperial College, London, UK
10 Clinique Pasteur, Toulouse, France
11 Heidelberg University, Ludwigshafen, Germany
12 Ospedali Riuniti di Bergamo, Bergamo, Italy
13 Trial Coordination Center, Department of Epidemiology, University Medical Center Groningen, the Netherlands
14 Department of Medical Sciences and Cardiology, Uppsala Clinical Research Center, University Hospital, Uppsala, Sweden
15 Division of Clinical Epidemiology and Biostatistics, Department of Social and Preventive Medicine, University of Bern, Bern, Switzerland
16 Deutsches Herzzentrum, Munich, Germany
17 TÜV SÜD Product Service GmbH, München, Germany
18 Department of Cardiology, Aarhus University Hospital, Skejby, Denmark
19 Duke University Medical Center/Duke Clinical Research Institute, Durham, NC, USA
20 CHU Sart-Tilman, Liège, Belgium
21 Departments of Cardiology, University Hospital, Basel, Switzerland
22 The London Chest Hospital, London, UK
23 Cardiology Practice and Hospital, Munich, Germany
24 Hôpital Bichat, Paris, France
25 BSI Product Services Healthcare
26 Bern University Hospital, Department of Cardiology, Bern, Switzerland
27 Biotronik GmbH & Co. KG, Berlin, Germany
28 Boston Scientific, Natick, Mass, USA
29 European Medicines Agency (EMEA), London, UK
30 Medpole, Neostent Corporation, Belgium
31 Center for Devices and Radiologic Health, United States Food and Drug Administration, Rockville, USA
32 Abbott Vascular, Santa Clara, CA, USA
33 Hexacath Corporation, France
34 Cordis Corporation, Johnson & Johnson Company, Miami Lakes, FL, USA
35 ClearStream Technologies Group plc, Wexford, Ireland
36 Sorin Biomedica, Saluggia, Italy
37 AFSAPS, Agence Française de Sécurité Sanitaire des Produits de Santé, Paris, France
38 Medtronic Vascular, Santa Rosa, CA, USA
39 Terumo Corporation, Tokyo, Japan
40 B Braun Medical BV, the Netherlands
| The first 150 words of the full text of this article appear below. |
 |
Introduction |
|---|
Drug-eluting stents (DES) were introduced into clinical practice in 2002 in order to reduce restenosis that occurred in 15–25% of patients receiving bare-metal stents (BMS).1–3 Subsequent trials with different types of DES confirmed their efficacy in this regard.4 However, late stent thrombosis was reported as early as 2004, typically in patients discontinuing dual anti-platelet therapy.5 At the European and World Congress of Cardiology in Barcelona 2006, alarming data were presented on a worse long-term prognosis following DES implantation compared with BMS.6,7 As a result both randomized controlled trials and registry data were scrutinized to validate these concerns, bearing in mind the differential values of both types of studies.8,9 Furthermore, the worldwide discussion on the long-term safety and efficacy of DES triggered the European Society of Cardiology together with the European Association for Percutaneous Cardiovascular Interventions to organize a forum on DES. On 27 and 28 September 2007, key opinion leaders
|
Safety |
|---|
Late stent thrombosis
|
Efficacy |
|---|
|
Drug eluting stents and bare-metal stents in specific patient groups |
|---|
ST-segment elevation myocardial infarction
Multivessel coronary artery disease
Small vessels, long lesions, diabetics, and bypass grafts
Conclusions, perspectives, and recommendations regarding efficacy and safety of DES
|
Health economical analyses |
|---|
Conclusions, perspectives, and recommendations on cost-effectiveness
UPDATE: NICE appraisal July 2008
|
The DES registration process |
|---|
|
A glimpse into future trial design |
|---|
Conclusions, perspectives, and recommendations for trial design, registration processes, and anti-platelet therapy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Rosenthal and M. A. Costa Unravelling the endovascular microenvironment by optical coherence tomography Eur. Heart J., November 19, 2009; (2009) ehp481v1. [Full Text] [PDF]
|
|